A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: Extending the Guyton model

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 306, Issue 9, 2014, Pages

  Hallow, K Melissa ^a   Lo, Arthur ^b   Beh, Jeni ^b   Rodrigo, Manoj ^b   Ermakov, Sergey ^b   Friedman, Stuart ^b   de Leon, Hector ^b   Sarkar, Anamika ^a   Xiong, Yuan ^a   Sarangapani, Ramesh ^a   Schmidt, Henning ^a   Webb, Randy ^a   Kondic, Anna Georgieva ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Entelos Holding Corporation   (United States)

Author keywords

Blood pressure; Hypertension; Renin angiotensin aldosterone system; Systems biology

Indexed keywords

ALDOSTERONE; ALISKIREN; ALISKIREN PLUS AMLODIPINE; ALISKIREN PLUS HYDROCHLOROTHIAZIDE; ALISKIREN PLUS VALSARTAN; AMLODIPINE; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN II; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIURETIC AGENT; ENALAPRIL; EPLERENONE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; LOSARTAN; RAMIPRIL; RENIN; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CALIBRATION; GUYTON MODEL; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY VASCULAR RESISTANCE; MODEL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; SIMULATION; SODIUM ABSORPTION;

BLOOD PRESSURE; HYPERTENSION; RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM; SYSTEMS BIOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; COMPUTER SIMULATION; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; KIDNEY; MODELS, CARDIOVASCULAR; RENIN-ANGIOTENSIN SYSTEM; REPRODUCIBILITY OF RESULTS; SYSTEMS BIOLOGY; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84900522345     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00039.2013     Document Type: Article

References (58)

1. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Managed Care Pharm 13: S9-S20, 2007.
2. Belz GG, Butzer R, Kober S, Mang C, Mutschler E. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay. Clin Pharm Ther 66: 367-373, 1999.
3. Brenner BM, Chertow GM. Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis 23: 171-175, 1994.
4. Bubien JK. Epithelial Na channel (ENaC) hormones, hypertension. J Biol Chem 285: 23527-23531, 2010.
5. Carmines PK, Inscho EW, Gensure RC. Arterial pressure effects on preglomerular microvasculature of juxtamedullary nephrons. Am J Physiol Renal Fluid Electrolyte Physiol 258: F94-F102, 1990.
6. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, Maggon K, Shum L, Timmermans PB, Brunner HR. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 83: 1333-1342, 1991.
7. Churchill PC. Effect of D-600 on inhibition of in vitro renin release in the rat by high extracellular potassium and angiotensin II. J Physiol 304: 449-458, 1980.
8. Coleman TG, Hall JE. A mathematical model of renal hemodynamics and excretory function. In: Structuring Biological Systems: A Computer Modelling Approach, edited by Iyengar SS. Boca Raton, FL: CRC, 1992.
9. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J, Wieland P, Wehrli HU. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240: 650-656, 1987.
10. Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS, Brown MJ. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 20: 771-777, 2002.
11. Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation in hypertension. Curr Opin Nephrol Hypertens 20: 647-653, 2011.
12. Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJ, Bjornsson TD. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 21: 704-713, 1993.
13. Grisk O, Rettig R. Interactions between the sympathetic nervous system and the kidneys in arterial hypertension. Cardiovasc Res 61: 238-246, 2004.
14. Guillaud F, Hannaert P. A computational model of the circulating renin-angiotensin system and blood pressure regulation. Acta Biotheor 58: 143-170, 2010.
15. Guyton AC. Long-term arterial pressure control: an analysis from animal experiments and computer graphic models. Am J Physiol Regul Integr Comp Physiol 259: R865-R877, 1990.
16. Guyton AC, Coleman TG, Granger HJ. Circulation: overall regulation. Annu Rev Physiol 34: 13-46, 1972.
17. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2 channel subtypes and pharmacology in the kidney. Circ Res 100: 342-353, 2007.
18. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev 4: CD003823, 2008.
19. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 4: CD003822, 2008.
20. Hernández AI, Le Rolle V, Ojeda D, Baconnier P, Fontecave-Jallon J, Guillaud F, Grosse T, Moss RG, Hannaert P, Thomas SR. Integration of detailed modules in a core model of body fluid homeostasis and blood pressure regulation. Prog Biophys Mol Biol 107: 169-182, 2011.
21. Hodsman GP, Zabludowski JR, Zoccali C, Fraser R, Morton JJ, Murray GD, Robertson JI. Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man. Br J Clin Pharmacol 17: 233-241, 1984.
22. Johnson JA, Gong Y, Bailey KR, Cooper-DeHoff RM, Chapman AB, Turner ST, Schwartz GL, Campbell K, Schmidt S, Beitelshees AL, Boerwinkle E, Gums JG. Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order. Clin Pharmacol Ther 86: 533-539, 2009.
23. Just A. Mechanisms of renal blood flow autoregulation: dynamics and contributions. Am J Physiol Regul Integr Comp Physiol 292: R1-R17, 2007.
24. Kammerl MC, Nusing RM, Richthammer W, Kramer BK, Kurtz A. Inhibition of COX-2 counteracts the effects of diuretics in rats. Kidney Int 60: 1684-1691, 2001.
25. Karaaslan F, Denizhan Y, Keyserilioglu A, Gulcur HO. Long-term mathematical model involving renal sympathetic nerve activity, arterial pressure, and sodium excretion. Ann Biomed Eng 33: 1607-1630, 2005.
26. Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med 348: 101-108, 2003.
27. LeFebvre J, Shintani A, Gebretsadik T, Petro JR, Murphey LJ, Brown NJ. Bradykinin B2 receptor does not contribute to blood pressure lowering during AT1 receptor blockade. J Pharmacol Exp Ther 320: 1261-1267, 2007.
28. Littlejohn TW 3rd, Jones SW, Zhang J, Hsu H, Keefe DL. Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study. J Hum Hypertens 27: 321-327, 2013.
29. Lo A, Beh J, de Leon H, Hallow KM, Ramakrishna R, Rodrigo M, Sarkar A, Sarangapani R, Georgieva A. Using a systems biology approach to explore hypotheses underlying clinical diversity of the renin angiotensin system and the response to antihypertensive therapies. In: Clinical Trial Simulations, edited by Kimko HC, Peck C. New York: Springer, 2011, vol. 1.
30. Loutzenhiser R, Bidani A, Chilton L. Renal myogenic response: kinetic attributes and physiological role. Circ Res 90: 1316-1324, 2002.
31. Maillard MP, Wurzner G, Nussberger J, Centeno C, Burnier M, Brunner HR. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 71: 68-76, 2002.
32. Montani JP, van Vliet BN. Understanding the contribution of Guyton's large circulatory model to long-term control of arterial pressure. Exp Physiol 94: 381-397, 2009.
33. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40: 897-902, 2002.
34. Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev 9: CD007066, 2011.
35. Navar LG. The kidney in blood pressure regulation and development of hypertension. Med Clin North Am 81: 1165-1198, 1997.
36. Nussberger J, Gradman AH, Schmieder RE, Lins RL, Chiang Y, Prescott MF. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract 61: 1461-1468, 2007.
37. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 39: e1-e8, 2002.
38. Nyengaard JR, Bendtsen TF. Glomerular number and size in relation to age, kidney weight, and body surface in normal man. Anat Rec 232: 194-201, 1992.
39. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 35: 290-297, 1993.
40. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370: 221-229, 2007.
41. Osborn JW, Averina VA, Fink GD. Current computational models do not reveal the importance of the nervous system in long-term control of arterial pressure. Exp Physiol 94: 381-397, 2009.
42. Pechere-Bertschi A, Nussberger J, Decosterd L, Armagnac C, Sissmann J, Bouroudian M, Brunner HR, Burnier M. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. J Hypertens 16: 385-393, 1998.
43. Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R. Two multicenter, 8-wk, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 29: 563-580, 2007.
44. Pimenta E, Gordon RD, Stowasser M. Salt, aldosterone, hypertension. J Hum Hypertens 27: 1-6, 2013.
45. Poirier L, de Champlain J, Larochelle P, Lamarre-Cliché M, Lacourciere Y. A comparison of the efficacy and duration of action of telmisartan, amlodipine, and ramipril in patients with confirmed ambulatory hypertension. Blood Press Monit 9: 231-236, 2004.
46. Pool JL, Glazer R, Weinberger M, Alvarado R, Huang J, Graff A. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebocontrolled study followed by long-term combination therapy in hypertensive adults. Clin Ther 29: 61-73, 2007.
47. Quinones-Galvan A, Ferrannini E. Renal effects of insulin in man. J Nephrol 10: 188-191, 1997.
48. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebocontrolled, active comparator study. Lancet 375: 1255-1266, 2010.
49. Saruta T, Kageyama S, Ogihara T, Hiwada K, Ogawa M, Tawara K, Gatlin M, Garthwaite S, Bittman R, Patrick J. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled. J Clin Hypertens (Greenwich) 6: 175-183, 2004.
50. Schmidt H, Jirstrand M. Systems Biology Toolbox for Matlab: a computational platform for research in systems biology. Bioinformatics 22: 514-515, 2006.
51. Skrabal F. Half-life of plasma renin activity in normal subjects and in malignant hypertension. Klin Wochenschr 52: 1173-1174, 1974.
52. Takahashi N, Hagman J, Kim H, Smithies O. Computer simulation of blood pressure regulation by the renin-angiotensin system. Endocrinology 144: 2184-2190, 2003.
53. Tomaschitz A, Pilz S, Ritz E, Obermayer-Pietsch B, Pieber TR. Aldosterone and arterial hypertension. Nat Rev Endocrinol 6: 83-93, 2010.
54. Ueshiba H, Miyachi Y. Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern Med 43: 561-565, 2004.
55. Uresin Y, Taylor AA, Kilo C, Tschope D, Santonastaso M, Ibram G, Fang H, Satlin A. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 8: 190-198, 2007.
56. Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 300: R1009-R1022, 2011.
57. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 25: 217-226, 2007.
58. White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W. Assessment of the novel selective aldosterone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 92: 38-42, 2003.